AAAAAA

   
Results: 1-12 |
Results: 12
HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide
Authors: Di Leo, A Larsimont, D Gancberg, D Jarvinen, T Beauduin, M Vindevoghel, A Michel, J Focan, C Ries, F Gobert, P Closon-Dejardin, MT Dolci, S Rouas, G Paesmans, M Lobelle, JP Isola, J Piccart, MJ
Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089
Phase II study of vinorelbine in patients with androgen-independent prostate cancer
Authors: Oudard, S Caty, A Humblet, Y Beauduin, M Suc, E Piccart, M Rolland, F Fumoleau, P Bugat, R Houyau, P Monnier, A Sun, X Montcuquet, P Breza, J Novak, J Gil, T Chopin, D
Citation: S. Oudard et al., Phase II study of vinorelbine in patients with androgen-independent prostate cancer, ANN ONCOL, 12(6), 2001, pp. 847-852
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
Authors: Piccart, MJ Di Leo, A Beauduin, M Vindevoghel, A Michel, J Focan, C Tagnon, A Ries, F Gobert, P Finet, C Closon-Dejardin, MT Dufrane, JP Kerger, J Liebens, F Beauvois, S Bartholomeus, S Dolci, S Lobelle, JP Paesmans, M Nogaret, JM
Citation: Mj. Piccart et al., Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J CL ONCOL, 19(12), 2001, pp. 3103-3110
PSA kinetics after external beam radiotherapy alone or combined with an iridium brachytherapy boost to deliver 85 Grays to prostatic adenocarcinoma
Authors: Nickers, P Coppens, L Beauduin, M Sabatier, J Albert, A de Leval, J Deneufbourg, JM
Citation: P. Nickers et al., PSA kinetics after external beam radiotherapy alone or combined with an iridium brachytherapy boost to deliver 85 Grays to prostatic adenocarcinoma, STRAH ONKOL, 177(2), 2001, pp. 90-95
Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13years update in a multicentre randomized trial
Authors: Focan, C Beauduin, M Salamon, E de Greve, J de Wasch, G Lobelle, JP Majois, F Tagnon, A Tytgat, J van Belle, S Vandervellen, R Vindevoghel, A
Citation: C. Focan et al., Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13years update in a multicentre randomized trial, BR J CANC, 85(1), 2001, pp. 1-8
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial
Authors: Focan, C Bury, J Beauduin, M Herman, ML Vindevoghel, A Brohee, D Lecomte, M
Citation: C. Focan et al., Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial, ANTI-CANC D, 11(7), 2000, pp. 549-554
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer
Authors: Focan, C Bury, J Beauduin, M Herman, ML Vindevoghel, A Lecomte, M Brohee, D Canon, JL Focan-Henrard, D
Citation: C. Focan et al., Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer, ANTICANC R, 20(6C), 2000, pp. 4665-4672
Feasibility study combining low dose rate Ir-192 brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma
Authors: Nickers, P Coppens, L Beauduin, M Darimont, M de Leval, J Deneufbourg, JM
Citation: P. Nickers et al., Feasibility study combining low dose rate Ir-192 brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma, RADIOTH ONC, 55(1), 2000, pp. 41-47
The effect of 2 '-2 ' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
Authors: Rosier, JF Beauduin, M Bruniaux, M De Bast, M De Coster, B Octave-Prignot, M Scalliet, P Gregoire, V
Citation: Jf. Rosier et al., The effect of 2 '-2 ' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity, INT J RAD B, 75(2), 1999, pp. 245-251
Radiotherapy of pelvic malignancies: impact of two types of rigid immobilisation devices on localisation errors
Authors: Mitine, C Hoornaert, MT Dutreix, A Beauduin, M
Citation: C. Mitine et al., Radiotherapy of pelvic malignancies: impact of two types of rigid immobilisation devices on localisation errors, RADIOTH ONC, 52(1), 1999, pp. 19-27
Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice
Authors: Gregoire, V Cvilic, S Beauduin, M De Coster, B Gueulette, J Octave-Prignot, M Scalliet, P
Citation: V. Gregoire et al., Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice, RADIAT RES, 151(6), 1999, pp. 747-749
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Authors: Marchand, M van Baren, N Weynants, P Brichard, V Dreno, B Tessier, MH Rankin, E Parmiani, G Arienti, F Humblet, Y Bourlond, A Vanwijck, R Lienard, D Beauduin, M Dietrich, PY Russo, V Kerger, J Masucci, G Jager, E De Greve, J Atzpodien, J Brasseur, F Coulie, PG Van der Bruggen, P Boon, T
Citation: M. Marchand et al., Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, INT J CANC, 80(2), 1999, pp. 219-230
Risultati: 1-12 |